Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib versus teriflunomide in relapsing multiple sclerosis
2019-004857-10Phase 3Active
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenebrutinib in multiple sclerosis (MS) (2 arms), sponsored by Roche. Primary endpoints: Annualized relapse rate and Time to onset of composite 12-week confirmed disability progression. Started Nov 2020; status: active.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-004857-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004857-10.